Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Colorectal Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Colon Cancer (151
)
Rectal Cancer (65
)
Colorectal Adenocarcinoma (8
)
Colon Cancer (151
)
Rectal Cancer (65
)
Colorectal Adenocarcinoma (8
)
›
Associations
(1218)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HER-2 amplification + RAS wild-type + BRAF wild-type
Colon Cancer
HER-2 amplification + RAS wild-type + BRAF wild-type
Colon Cancer
trastuzumab + tucatinib
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
trastuzumab + tucatinib
Sensitive
:
A2
NCCN - 1wk
trastuzumab + tucatinib
Sensitive: A2 - Guideline
NCCN - 1 week
trastuzumab + tucatinib
Sensitive
:
A2
NCCN - 1 week - (New A2)
RAS wild-type + HER-2 positive
Colorectal Cancer
RAS wild-type + HER-2 positive
Colorectal Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
FDA - 2 weeks (New A1)
trastuzumab + tucatinib
Sensitive
:
A1
FDA - 2wk
trastuzumab + tucatinib
Sensitive: A1 - Approval
FDA - 2 weeks
trastuzumab + tucatinib
Sensitive
:
A1
FDA - 2 weeks - (New A1)
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
Immunotherapy
Sensitive
:
C3
ASCO-GI 2023 - 2wk
Immunotherapy
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
Immunotherapy
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
EREG overexpression + AREG overexpression
Colorectal Cancer
EREG overexpression + AREG overexpression
Colorectal Cancer
panitumumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
panitumumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
panitumumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
panitumumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
erlotinib + vemurafenib
Sensitive: C3 – Early Trials
Clin Cancer Res - 2 weeks (New C3)
erlotinib + vemurafenib
Sensitive
:
C3
Clin Cancer Res - 2wk
erlotinib + vemurafenib
Sensitive: C3 – Early Trials
Clin Cancer Res - 2 weeks
erlotinib + vemurafenib
Sensitive
:
C3
Clin Cancer Res - 2 weeks - (New C3)
RAS wild-type
Colorectal Cancer
RAS wild-type
Colorectal Cancer
anlotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
anlotinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
anlotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
anlotinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type
Colorectal Cancer
RAS wild-type
Colorectal Cancer
cetuximab + tislelizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
cetuximab + tislelizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
cetuximab + tislelizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
cetuximab + tislelizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
BRAF wild-type + HER-2 positive
Colorectal Cancer
BRAF wild-type + HER-2 positive
Colorectal Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type + HER-2 positive
Colorectal Cancer
RAS wild-type + HER-2 positive
Colorectal Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MUC16 elevation
Colorectal Cancer
MUC16 elevation
Colorectal Cancer
regorafenib
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
regorafenib
Resistant
:
C3
ASCO-GI 2023 - 2wk
regorafenib
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
regorafenib
Resistant
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MUC16 elevation
Colorectal Cancer
MUC16 elevation
Colorectal Cancer
trifluridine/tipiracil
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trifluridine / tipiracil
Resistant
:
C3
ASCO-GI 2023 - 2wk
trifluridine/tipiracil
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trifluridine / tipiracil
Resistant
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CEACAM5 underexpression + MSI-H/dMMR
Colorectal Cancer
CEACAM5 underexpression + MSI-H/dMMR
Colorectal Cancer
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab + ipilimumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab + ipilimumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CEACAM5 underexpression + MSI-H/dMMR
Colorectal Cancer
CEACAM5 underexpression + MSI-H/dMMR
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
THBS2-L
Colorectal Cancer
THBS2-L
Colorectal Cancer
ramucirumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ramucirumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ramucirumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ramucirumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + CD74 overexpression
Colorectal Cancer
MSI-H/dMMR + CD74 overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQA1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DQA1 overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DPA1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DPA1 overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DQB1 overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-B overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-B overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DRB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DRB1 overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQA1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DQA1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + CD74 overexpression
Colorectal Cancer
MSI-H/dMMR + CD74 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DPA1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DPA1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DQB1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-B overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-B overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DRB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DRB1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
EREG overexpression + AREG overexpression
Colorectal Cancer
EREG overexpression + AREG overexpression
Colorectal Cancer
cetuximab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
cetuximab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
cetuximab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
cetuximab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + RAS mutation
Colorectal Cancer
MSI-H/dMMR + RAS mutation
Colorectal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
Immunotherapy
Sensitive
:
C3
ASCO-GI 2023 - 2wk
Immunotherapy
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
Immunotherapy
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression
Colorectal Cancer
PD-L1 expression
Colorectal Cancer
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2wk
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
NRAS mutation
Colorectal Cancer
NRAS mutation
Colorectal Cancer
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2wk
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2wk
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
PIK3CA mutation
Colorectal Cancer
PIK3CA mutation
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
MSI-H/dMMR + HLA-DPB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DPB1 overexpression
Colorectal Cancer
nivolumab
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
nivolumab
Sensitive
:
D
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
MSI-H/dMMR + HLA-DPB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DPB1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
pembrolizumab
Sensitive
:
D
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA mutation + KRAS mutation
Colorectal Cancer
PIK3CA mutation + KRAS mutation
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA wild-type + KRAS wild-type
Colorectal Cancer
PIK3CA wild-type + KRAS wild-type
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
ROS1 amplification
Colon Cancer
ROS1 amplification
Colon Cancer
metformin + efavirenz + fluoxetine
Sensitive: D – Preclinical
Cancer Biol Ther - 4 weeks (New D)
metformin + efavirenz + fluoxetine
Sensitive
:
D
Cancer Biol Ther - 4wk
metformin + efavirenz + fluoxetine
Sensitive: D – Preclinical
Cancer Biol Ther - 4 weeks
metformin + efavirenz + fluoxetine
Sensitive
:
D
Cancer Biol Ther - 4 weeks - (New D)
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + encorafenib + binimetinib
Sensitive: A1 - Approval
cetuximab + encorafenib + binimetinib
Sensitive
:
A1
cetuximab + encorafenib + binimetinib
Sensitive: A1 - Approval
cetuximab + encorafenib + binimetinib
Sensitive
:
A1
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + encorafenib
Sensitive: A1 - Approval
cetuximab + encorafenib
Sensitive
:
A1
cetuximab + encorafenib
Sensitive: A1 - Approval
cetuximab + encorafenib
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
capecitabine
Sensitive: A1 - Approval
capecitabine
Sensitive
:
A1
capecitabine
Sensitive: A1 - Approval
capecitabine
Sensitive
:
A1
No biomarker
Rectal Cancer
No biomarker
Rectal Cancer
FOLFIRI
Sensitive: A1 - Approval
FOLFIRI
Sensitive
:
A1
FOLFIRI
Sensitive: A1 - Approval
FOLFIRI
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive: A1 - Approval
5-fluorouracil + irinotecan
Sensitive
:
A1
5-fluorouracil + irinotecan
Sensitive: A1 - Approval
5-fluorouracil + irinotecan
Sensitive
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
No biomarker
Rectal Cancer
No biomarker
Rectal Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
bevacizumab-bvzr
Resistant: A1 - Approval
bevacizumab-bvzr
Resistant
:
A1
bevacizumab-bvzr
Resistant: A1 - Approval
bevacizumab-bvzr
Resistant
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
trifluridine/tipiracil
Sensitive: A1 - Approval
trifluridine / tipiracil
Sensitive
:
A1
trifluridine/tipiracil
Sensitive: A1 - Approval
trifluridine / tipiracil
Sensitive
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
ziv-aflibercept IV
Sensitive: A1 - Approval
ziv-aflibercept IV
Sensitive
:
A1
ziv-aflibercept IV
Sensitive: A1 - Approval
ziv-aflibercept IV
Sensitive
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
capecitabine
Sensitive: A1 - Approval
capecitabine
Sensitive
:
A1
capecitabine
Sensitive: A1 - Approval
capecitabine
Sensitive
:
A1
EGFR expression
Colorectal Cancer
EGFR expression
Colorectal Cancer
cetuximab
Sensitive: A1 - Approval
cetuximab
Sensitive
:
A1
cetuximab
Sensitive: A1 - Approval
cetuximab
Sensitive
:
A1
KRAS Q61
Colorectal Cancer
KRAS Q61
Colorectal Cancer
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
KRAS A146
Colorectal Cancer
KRAS A146
Colorectal Cancer
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
No biomarker
Rectal Cancer
No biomarker
Rectal Cancer
irinotecan
Sensitive: A1 - Approval
irinotecan
Sensitive
:
A1
irinotecan
Sensitive: A1 - Approval
irinotecan
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
irinotecan
Sensitive: A1 - Approval
irinotecan
Sensitive
:
A1
irinotecan
Sensitive: A1 - Approval
irinotecan
Sensitive
:
A1
KRAS G13
Colorectal Cancer
KRAS G13
Colorectal Cancer
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
KRAS G12
Colorectal Cancer
KRAS G12
Colorectal Cancer
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
KRAS K117
Colorectal Cancer
KRAS K117
Colorectal Cancer
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
KRAS A59
Colorectal Cancer
KRAS A59
Colorectal Cancer
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
KRAS G12S
Colorectal Cancer
KRAS G12S
Colorectal Cancer
panitumumab
Resistant: A1 - Approval
panitumumab
Resistant
:
A1
panitumumab
Resistant: A1 - Approval
panitumumab
Resistant
:
A1
NRAS Q61
Colorectal Cancer
NRAS Q61
Colorectal Cancer
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
NRAS Q61
Colorectal Cancer
NRAS Q61
Colorectal Cancer
panitumumab
Resistant: A1 - Approval
panitumumab
Resistant
:
A1
panitumumab
Resistant: A1 - Approval
panitumumab
Resistant
:
A1
NRAS G13
Colorectal Cancer
NRAS G13
Colorectal Cancer
panitumumab
Resistant: A1 - Approval
panitumumab
Resistant
:
A1
panitumumab
Resistant: A1 - Approval
panitumumab
Resistant
:
A1
NRAS G13
Colorectal Cancer
NRAS G13
Colorectal Cancer
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login